61324-40-1

Usage

Uses

Used in Pharmaceutical Industry:
3-(Benzyloxy)-4-methoxyaniline is used as an intermediate in organic synthesis for the manufacturing of pharmaceuticals. Its unique structure allows for the development of various drug candidates with potential therapeutic applications.
Used in Agrochemical Industry:
3-(Benzyloxy)-4-methoxyaniline is also used as an intermediate in the synthesis of agrochemicals, contributing to the development of effective pesticides and other agricultural products.
Used in Research and Development:
3-(Benzyloxy)-4-methoxyaniline is utilized in research and development for studying its potential biological activities, such as antimicrobial and anticancer properties. This can lead to the discovery of new treatments and applications in medicine and other fields.
Safety Precautions:
3-(Benzyloxy)-4-methoxyaniline is considered a hazardous material and should be handled and stored with proper precautions to prevent adverse health effects. It is essential to follow safety guidelines and regulations when working with 3-(benzyloxy)-4-methoxyaniline.

Upstream product

• 100-39-0 benzyl bromide 
• 1687-53-2 5-amino-2-methoxyphenol 
• 67233-85-6 sodium 5-nitroguaiacolate 
• 64-17-5 ethanol 
• 75167-86-1 2-(benzyloxy)-1-methoxy-4-nitrobenzene 
• 636-93-1 5-nitroguaiacol 
• 100-44-7 benzyl chloride 
• 224450-48-0 tert-butyl N-(3-hydroxy-4-methoxyphenyl)carbamate 

Downstream Products

• 329008-82-4 (3-benzyloxy-4-methoxy-phenyl)-(3,4,5-trimethoxy-phenyl)-amine 
• 561277-16-5 N-(3-benzyloxy-4-methoxy-phenyl)-N'-(2-chloro-phenyl)-ethane-1,2-diamine 
• 561277-14-3 N-(3-benzyloxy-4-methoxy-phenyl)-N'-(3-fluoro-phenyl)-ethane-1,2-diamine 
• 561277-15-4 N-(3-benzyloxy-4-methoxy-phenyl)-N'-(4-methyl-3-trifluoromethyl-phenyl)-ethane-1,2-diamine 
• 61324-41-2 2-[(3-Benzyloxy-4-methoxy-phenylamino)-methylene]-malonic acid diethyl ester 
• 516526-44-6 4-(2-fluoro-4-nitro-phenoxy)-6,7-dimethoxy-quinoline 

Relevant academic research and scientific papers

Synthesis and evaluation of azalamellarin N and its A-ring-modified analogues as non-covalent inhibitors of the EGFR T790M/L858R mutant

Azalamellarin N, a synthetic lactam congener of the marine natural product lamellarin N, and its A-ring-modified analogues were synthesized and evaluated as potent and non-covalent inhibitors of the drug-resistant epidermal growth factor receptor T790M/L8

Discovery of AL-GDa62 as a Potential Synthetic Lethal Lead for the Treatment of Gastric Cancer

Diffuse gastric cancer and lobular breast cancer are aggressive malignancies that are frequently associated with inactivating mutations in the tumor suppressor gene CDH1. Synthetic lethal (SL) vulnerabilities arising from CDH1 dysfunction represent attrac

Discovery of 1,6-naphthyridinone-based MET kinase inhibitor bearing quinoline moiety as promising antitumor drug candidate

A series of 1,6-naphthyridinone-based MET kinase inhibitors bearing quinoline moiety in block A were designed and synthesized based on the structures of Cabozantinib and our reported compound IV. Extensive SAR and DMPK studies led to the identification of 20j, a potent and orally bioavailable MET kinase inhibitor with favorable kinase selectivity. More importantly, 20j exhibited statistically significant tumor growth inhibition (Tumor growth inhibition/TGI of 131%, 4/6 partial regression/PR) in the U-87 MG xeograft model, which is superior to that of Cabozantinib (TGI of 97%, 2/6 PR), and significantly better than that of compound IV (TGI of 15%, 0/6 PR) at the same dose (12.5 mg/kg). Combined with favorable in vitro potency, kinase selectivity, pharmacokinetic profile and in vivo efficacy, the promising antitumor drug candidate 20j has subsequently advanced into preclinical research.

COMPLEMENT MODULATORS AND RELATED METHODS

The present disclosure presents compounds and compositions that interact with complement components. Some compounds inhibit complement activity. Included are small molecule compounds and compositions that function as C5 inhibitor compounds. Methods for inhibiting complement activity and methods of treating complement-related indications with the C5 inhibitor compounds and compositions are provided.

Preparation method of 7-benzyloxy-6-methoxy-4-hydroxyquinoline

The invention discloses a preparation method of 7-benzyloxy-6-methoxy-4-hydroxyquinoline. The method comprises the following steps: under the action of anhydrous p-methylbenzenesulfonic acid, carrying out condensation reaction on 3-benzyloxy-4-methoxyanil

Naphthyridine compound and pharmaceutical composition as well as applications thereof

The invention relates to the field of biological medicines and discloses a naphthyridine compound and a pharmaceutical composition as well as applications thereof. The naphthyridine compound has a structure shown in a formula (I) or a stereisomer, a geometric isomer, a tautomer, nitric oxide, hydrate, solvate, metabolite, a pharmaceutically acceptable salt or a prodrug. The naphthyridine compound disclosed by the invention has an anti-tumor effect which is obviously superior to the anti-tumor effect of the prior art. And moreover, the naphthyridine compound disclosed by the invention can treat diseases mediated by protein kinase.

Aryloxy quinoline derivatives and their use in therapy

Disclosed herein are aryloxy quinolines derivatives,and the said compounds are compounds of formula (I) or pharmaceutically acceptable salts thereof or solvates, wherein R1, R2, R3, R4, m, n, X, Z, Ar are defined detailedly in the description. Furthermore, medicaments comprising said compounds or salts as active components and the use for treating conditions and disorders relating to protein-tyrosine kinase receptors, especially c-Met, VEGFR are also described.

Synthesis and anticancer activity of 4-aza-daurinol derivatives

Daurinol, a natural aryl naphthalene lactone, has been reported to have antiproliferative activity against various cell lines, and has also been shown to be efficacious in an in vivo xenograft mouse model. In this study, we tried to discover a new scaffold that enables both rapid structure-activity relationship study of daurinol and scalable synthesis of active compounds. 4-Aza-daurinol, a bioisosterism-based scaffold of daurinol, was designed and 17 analogues were synthesized and evaluated against five representative cancer cell lines. Among them, the 2,3-dihydrobenzo[b][1,4]dioxinyl derivative was found to be the most potent and showed similar activity and tendency as daurinol.

Identification of 3-amido-4-anilinoquinolines as potent and selective inhibitors of CSF-1R kinase

3-Amido-4-anilinoquinolines are potent and highly selective inhibitors of CSF-1R. Their synthesis and SAR is reported, along with initial efforts to optimize the physical properties and PK through modifications at the quinoline 6- and 7-positions.

QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY

Compounds of formula (IA) or (IB), are inhibitors of aurora kinase activity: Formula (IA), (IB) wherein -L1Y1-[CH2]z- is a linker radical wherein Y1, L1 and z are as defined in the claims; R6 is C1-C4alkoxy, hydrogen or halo; W represents a bond, -CH2-, -O-, -S-, -S(=O)2-, or -NR5- where R5 is hydrogen or C1-C4 alkyl; Q is =N-, =CH- or =C(X1)- wherein X1 is cyano, cyclopropyl or halo; linker radicals L2 are as defined in the claims; R is a radical of formula (X) or (Y): wherein R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R4 is hydrogen; or optionally substituted C1-C6 alkyl, C3-C7 cycloalkyl, aryl, aryl(C1-C6 alkyl)-, heteroaryl, heteroaryl(C1-C6 alkyl)-, -(C=O)R3, -(C=O)OR3, or -(C=O)NR3 wherein R3 is hydrogen or optionally substituted (C1-C6)alkyl, C3-C7 cycloalkyl, aryl, aryl(C1-C6 alkyl)-, heteroaryl, or heteroaryl(C1-C6 alkyl)-; R41 is hydrogen or optionally substituted C1-C6 alkyl; and D is a monocyclic heterocyclic ring of 5 or 6 ring atoms.